IceCure Medical Ltd. Ordinary Shares
ICCMIceCure Medical Ltd. is a medical technology company specializing in cryoablation solutions for minimally invasive treatment of tumors. Founded in Israel, the company develops and commercializes advanced cryoablation systems designed to precisely destroy cancerous tissues, primarily in breast, kidney, liver, and lung cancers. IceCure's innovative devices leverage liquid nitrogen and other cryogenic techniques to provide outpatient treatment options with reduced recovery times.
Company News
IceCure Medical expects record fourth quarter sales in North America following FDA clearance of ProSenseĀ® Cryoablation for low-risk breast cancer treatment, with strong interest from medical institutions and growing market demand.
IceCure Medical presented four independent studies at the Radiological Society of North America's Annual Meeting, highlighting the effectiveness of their ProSenseĀ® Cryoablation technology for non-surgical breast cancer treatment in patients who are not eligible for surgery.
IceCure Medical received a patent allowance in China for a novel cryogen flow control technology that optimizes patient cryoablation outcomes, enhancing temperature control and treatment effectiveness for tumor destruction.
IceCure Medical received regulatory approval in Switzerland for its ProSenseĀ® Cryoablation System, expanding its market access for cancer treatment across breast, lung, liver, and kidney cancer indications.
A study published in PLOS One demonstrates that IceCure's Cryoablation System combined with radiation therapy achieved a 92% disease-specific 5-year survival rate for stage I non-small cell lung cancer patients with tumors ā„2 cm.
